Literature DB >> 20426795

Use of antipsychotic drugs in individuals with intellectual disability (ID) in the Netherlands: prevalence and reasons for prescription.

Gerda de Kuijper1, P Hoekstra, F Visser, F A Scholte, C Penning, H Evenhuis.   

Abstract

BACKGROUND: We investigated antipsychotic drug prescription practice of Dutch ID physicians, studying prevalence of antipsychotic drug use, reasons for prescription and the relationship between these reasons and patient characteristics.
METHODS: A cross-sectional study of medical and pharmaceutical records in a population living in residential settings of three care providers for persons with IDs in the Netherlands (n = 2373).
RESULTS: Prevalence of antipsychotic drug use was 32.2% (95% CI 30.1-33.9). Behavioural problems were the reason for prescription of antipsychotic drugs in 58% of cases and psychotic disorder or psychotic symptoms in 22.5%. In 11.7% the diagnosis of psychotic disorder was specified according to DSM-IV criteria. In 18.5% the reason for prescription was not noted in the medical record. Behavioural problems as reason for prescription was associated with profound and severe ID, living in a central location and male sex. Psychotic disorder specified according to DSM-IV as indication for prescription was negatively associated with profound and severe ID and with presence of an additional mental disorder. Absence of a noted reason for prescription was associated with female sex and with the presence of an additional mental disorder. DISCUSSION: Current prevalence and reason for prescription of antipsychotic drugs are similar with outcomes of previous studies. Our results show the continuing lack of evidence-based psychopharmacological treatment in mental health care for persons with IDs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20426795     DOI: 10.1111/j.1365-2788.2010.01275.x

Source DB:  PubMed          Journal:  J Intellect Disabil Res        ISSN: 0964-2633


  28 in total

Review 1.  Polypharmacy in the treatment of subjects with intellectual disability.

Authors:  Frank Häβler; Johannes Thome; Olaf Reis
Journal:  J Neural Transm (Vienna)       Date:  2014-05-25       Impact factor: 3.575

2.  Primary care of adults with developmental disabilities: Canadian consensus guidelines.

Authors:  William F Sullivan; Joseph M Berg; Elspeth Bradley; Tom Cheetham; Richard Denton; John Heng; Brian Hennen; David Joyce; Maureen Kelly; Marika Korossy; Yona Lunsky; Shirley McMillan
Journal:  Can Fam Physician       Date:  2011-05       Impact factor: 3.275

3.  Prevalence of psychotropic drug use in adults with intellectual disability: positive and negative findings from a large scale study.

Authors:  John A Tsiouris; Soh-Yule Kim; W Ted Brown; Jill Pettinger; Ira L Cohen
Journal:  J Autism Dev Disord       Date:  2013-03

4.  Cognitive Behavioral Therapy for Depressed Adults with Mild Intellectual Disability: A Pilot Study.

Authors:  Sigan L Hartley; Anna J Esbensen; Rebecca Shalev; Lori B Vincent; Iulia Mihaila; Paige Bussanich
Journal:  J Ment Health Res Intellect Disabil       Date:  2015-04-06

5.  [Determinants of psychotropic medication in adults with mild or moderate intellectual disabilities].

Authors:  M Schützwohl; E Voss; M Stiawa; H-J Salize; B Puschner; A Koch
Journal:  Nervenarzt       Date:  2017-11       Impact factor: 1.214

6.  Drug burden index to define the burden of medicines in older adults with intellectual disabilities: An observational cross-sectional study.

Authors:  Juliette O'Connell; Éilish Burke; Niamh Mulryan; Claire O'Dwyer; Clare Donegan; Philip McCallion; Mary McCarron; Martin C Henman; Máire O'Dwyer
Journal:  Br J Clin Pharmacol       Date:  2018-01-05       Impact factor: 4.335

7.  Resource use and cost of annual health checks in primary care for people with intellectual disabilities.

Authors:  M Panca; M Buszewicz; A Strydom; A Hassiotis; C A Welch; R M Hunter
Journal:  J Intellect Disabil Res       Date:  2018-11-21

8.  Dual Diagnosis: A Problematic Construct When Applied to Persons with Intellectual Disabilities.

Authors:  John D McLennan
Journal:  Can J Psychiatry       Date:  2018-04-19       Impact factor: 4.356

9.  Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect.

Authors:  Michael Fralick; Chana A Sacks; Aaron S Kesselheim
Journal:  JAMA Intern Med       Date:  2019-02-01       Impact factor: 21.873

10.  Gonadotropin-releasing hormone agonist against severe aggression in autism.

Authors:  Robin M F van der Weiden; Frans M Helmerhorst; Tomas Eriksson
Journal:  BMJ Case Rep       Date:  2016-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.